The Foundation for Peripheral Neuropathy (FPN) applauds action taken by Congress to designate “peripheral neuropathy” as a condition eligible for research funding from the Department of Defense’s (DoD) Peer Reviewed... read more →
For most of the past two months, Congress – like most of the country – has been in lockdown and working remotely to respond to the COVID-19 pandemic. This has... read more →
The Foundation for Peripheral Neuropathy is embarking on a new and heightened campaign to make more funding available for research on peripheral neuropathy. For 2020, we are building on our... read more →
Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington DC, confirmed that the President and Congressional leaders recently reached... read more →
Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington DC, provided an update on FPN’s efforts to include peripheral... read more →
Your voice can help increase spending for research on peripheral neuropathy! The Foundation for Peripheral Neuropathy has initiated an advocacy program to promote more government spending on peripheral neuropathy research... read more →
On July 9, 2018, the Federal Drug Administration (FDA) held a public forum focusing on the patient’s perspective on drug development for chronic pain. The FDA invited members of the... read more →
The U.S. Department of Health and Human Services (HHS) has deemed May 12-16, 2016 National Neuropathy Awareness Week! The cornerstone of The Foundation for Peripheral Neuropathy's mission is to raise... read more →
On December 3, 2015, Astellas Pharma US, Inc. (the U.S. affiliate of Astellas Pharma Inc.), a R&D-driven global pharmaceutical company, invited the Foundation for Peripheral Neuropathy to present to a... read more →